"10.1371_journal.pone.0122037","plos one","2015-03-27T00:00:00Z","Melanie Ramberger; Patrick Peschl; Kathrin Schanda; Regina Irschick; Romana Höftberger; Florian Deisenhammer; Kevin Rostásy; Thomas Berger; Josep Dalmau; Markus Reindl","Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria; Division of Neuroanatomy, Medical University of Innsbruck, Innsbruck, Austria; Institute of Neurology, Medical University of Vienna, Vienna, Austria; Institució Catalana de Recerca i Estudis Avançats (ICREA), IDIBAPS, Hospital Clínic, Barcelona, Spain; Pediatric Neurology, Witten/Herdecke University, Children’s Hospital Datteln, Datteln, Germany","Conceived and designed the experiments: M. Ramberger M. Reindl. Performed the experiments: M. Ramberger PP KS RI M. Reindl. Analyzed the data: M. Ramberger M. Reindl. Contributed reagents/materials/analysis tools: RH FD KR TB JD. Wrote the paper: M. Ramberger RH JD M. Reindl.","JD has received a research grant from Euroimmun and holds a patent (Methods and compositions for treatment and diagnosis of encephalitis or epilepsy, USA patent number 7,972,796 B2, Europe EP 2 057 466) for the use of NMDA receptor as autoantibody test; he receives royalties for this antibody testing. RH and FD offer commercial testing for NMDA receptor antibodies. Markus Reindl is a PLOS ONE Editorial Board member. This does not alter the authors adherence to PLOS ONE Editorial policies and criteria.","2015","03","Melanie Ramberger","MR",10,TRUE,1,1,1,1,TRUE,TRUE,TRUE,3,"2;3;4",TRUE
